Advertisement

Unexpected Sensitivity of Nonobese Diabetic Mice With a Disrupted Poly(ADP-Ribose) Polymerase-1 Gene to Streptozotocin-Induced and Spontaneous Diabetes

  1. Cristina Gonzalez1,
  2. Josiane Ménissier de Murcia2,
  3. Philip Janiak3,
  4. Jean-Pierre Bidouard3,
  5. Catherine Beauvais1,
  6. Saoussen Karray1,
  7. Henri-Jean Garchon1 and
  8. Matthieu Lévi-Strauss1
  1. 1Institut National de la Santé et de la Recherche Médicale, Unité 25, Hôpital Necker, Paris, France
  2. 2Centre National de la Recherche Scientifique, Ecole Supérieure de Biotechnologie de Strasbourg, Illkirch, France
  3. 3Sanofi-Synthélabo Recherche, Département Cardio-Vasculaire, Chilly Mazarin Cedex, France

    Abstract

    Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that consumes NAD in response to DNA strand breaks. Its excessive activation seems particularly deleterious to pancreatic β-cells, as exemplified by the complete resistance of PARP-1-deficient mice to the toxic diabetes induced by streptozotocin. Because of the possible implication of this enzyme in type 1 diabetes, many human trials using nicotinamide, an inhibitor of PARP-1, have been conducted either in patients recently diagnosed or in subjects highly predisposed to this disease. To analyze the role of this enzyme in murine type 1 diabetes, we introgressed a disrupted PARP-1 allele onto the autoimmune diabetes-prone nonobese diabetic (NOD) mouse strain. We showed that these mice were protected neither from spontaneous nor from cyclophosphamide-accelerated diabetes. Surprisingly they were also highly sensitive to the diabetes induced by a single high dose of streptozotocin, standing in sharp contrast with C57BL/6 mice that bear the same inactivated PARP-1 allele. Our results suggest that NOD mice are characterized not only by their immune dysfunction but also by a peculiarity of their islets leading to a PARP-1-independent mechanism of streptozotocin-induced β-cell death.

    Footnotes

    • Address correspondence and reprint requests to Matthieu Lévi-Strauss, INSERM, Unité 25, Hôpital Necker, 161 rue de Sèvres, 75743 Paris Cedex 15, France. E-mail: lstrauss{at}infobiogen.fr.

      Received for publication 17 December 2001 and accepted in revised form 31 January 2002.

      P.J. and J.-P.B. are employees of Sanofi-Synthelabo Research, which manufactures and markets pharmaceuticals related to the treatment of diabetes and its complications.

      MEM, minimum essential medium; PARP, poly(ADP-ribose) polymerase; SPF, specific pathogen free.

    | Table of Contents
    Advertisement